Optiscan Imaging (OIL) ASX Gems Investment Conference summary

Strategic transformation and market expansion

• Transitioned from OEM manufacturing to private label, launching products under its own brand over the past three years.

• Diversified portfolio to include hardware, software, and services for medical, veterinary, and life sciences sectors, with a focus on robotics, telepathology, and AI.

• Established key partnerships with Mayo Clinic, University of Mainz, University of Minnesota Vet College, and Monash University, driving product development across clinical, veterinary, and life sciences markets.

• Expanded global presence with business development and sales operations in the US, EU, China, and Australia, including a Minnesota hub and clinical partnerships at Royal Melbourne Hospital.

• Strategic transformation and growth phases aim for significant market share in digital health, with expansion into new clinical and research markets through 2027 and beyond.

Product development and regulatory progress

• Launched InVue surgical device and InForm pathology device, both now in production, with regulatory pathways defined and submissions planned through FY26.

• Veterinary device collaboration with University of Minnesota on track for market reveal and FDA submission in the next quarter, with launch projected for Q1FY26.

• Continued R&D on flexible endomicroscope, GI flexible scope, and robotics, with hardware configurations largely completed.

• Product pipeline spans veterinary, surgical, pathology, oral, and telepathology applications, with multiple products in clinical and regulatory stages through 2027.

• Accelerated regulatory submission for InForm, targeting significant progress within 6–12 months.

Financial performance and outlook

• Maintained a strong balance sheet with AUD 11.2 million in FY 2024 and about AUD 7 million as of February 2025.

• FY25 total income projected to increase up to 20% to approximately $4.2m, driven by product sales and non-dilutive funding.

• Projected revenue growth from ViewnVivo and veterinary products in FY 2025–2026, with ViewnVivo sales expected to nearly double in FY25.

• Additional AUD 1 million in R&D tax incentives expected, with ongoing pursuit of non-dilutive funding.

• Planning for significant commercialization and revenue growth post-FY 2027 following regulatory clearances.